Cryoport, Inc. CYRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
0.96
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $176.2M | $78.3M | $83.1M | -$25.0M | $502.6M |
| 2024 | $156.8M | -$114.8M | $69.7M | -$33.6M | $401.9M |
| 2023 | $168.7M | -$99.6M | $75.3M | -$39.5M | $489.0M |
| 2022 | $237.3M | -$37.3M | $103.9M | -$24.0M | $555.8M |
| 2021 | $222.6M | -$275.5M | $96.6M | -$15.8M | $641.8M |
| 2020 | $78.7M | -$32.7M | $36.3M | -$23.8M | $382.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | 2026-06-11 | Option exercise | 33,600 | $4.80 |
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | 2026-06-11 | Sell | 33,600 | $14.47 |
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | 2026-06-10 | Option exercise | 1,400 | $4.80 |
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | 2026-06-10 | Sell | 1,400 | $15.23 |
| Mandalam Ramkumar | director | 2026-06-08 | Sell | 23,214 | $15.44 |
| Hariri Robert J | director | 2026-06-05 | Grant | 10,350 | — |
| BADDOUR LINDA | director | 2026-06-05 | Grant | 10,350 | — |
| HANCOCK DANIEL M | director | 2026-06-05 | Grant | 10,350 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.96 (distress)
- Working capital / assets 0.336
- Retained earnings / assets -0.901
- EBIT / assets -0.048
- Equity / liabilities 1.916
Source: SEC EDGAR filings · CIK 0001124524 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.